An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.
about
Gu-4 suppresses affinity and avidity modulation of CD11b and improves the outcome of mice with endotoxemia and sepsisTolerability, pharmacokinetics and pharmacodynamics of CMAB001, an anti-CD11a antibody, in Chinese healthy volunteers and psoriatic patients.Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab.Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.Heterogeneity of inflammatory and cytokine networks in chronic plaque psoriasis.Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects.Update of the management of chronic psoriasis: new approaches and emerging treatment options.Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockadeFatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control.Mechanistic determinants of biotherapeutics absorption following SC administration.Modulation of Immunity and the Inflammatory Response: A New Target for Treating Drug-resistant Epilepsy.Mechanisms of leukocyte migration across the blood-retina barrier.Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors.Therapeutic monoclonal antibody concentration monitoring: free or total?Theoretical considerations and practical approaches to address the effect of anti-drug antibody (ADA) on quantification of biotherapeutics in circulation.Strategies to address drug interaction potential for antibody-drug conjugates in clinical development.Review on modeling anti-antibody responses to monoclonal antibodies.Drug Development of Therapeutic Monoclonal Antibodies.Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies.Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.Pharmacokinetics and absolute bioavailability of mepolizumab following administration at subcutaneous and intramuscular sites.Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects.In silico database screening of potential targets and pathways of compounds contained in plants used for psoriasis vulgaris.Affinity maturation of an anti-V antigen IgG expressed in situ through adenovirus gene delivery confers enhanced protection against Yersinia pestis challenge.Mechanism of immunopotentiation and safety of aluminum adjuvants.A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation.Alefacept combined with tacrolimus, mycophenolate mofetil and steroids in de novo kidney transplantation: a randomized controlled trial.Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon.
P2860
Q28480469-8C54F521-FD12-41FC-8A2F-F4D2BD6BD1B0Q33571293-133C299D-19D2-4DD0-A961-62E7ED80DC93Q34026630-BA4C2882-31E9-46ED-A2C0-1574F4483940Q34204024-7141ED21-FB1F-44B3-A889-90FC617C5988Q34222693-BDFB9315-5991-48B7-B234-3A02EF004F3BQ34614211-01E615BE-3A26-4F2B-B1F2-356BA9DB2AF0Q34620375-C3A53FB0-63FE-4FBE-9A5A-A94EC237A356Q34976218-A4FE2711-0117-49F3-A71F-4EF3E91AB1C7Q35758657-C3A95927-AD23-4312-B5E3-856621701D1FQ36065572-A162AC09-5888-4CBE-A557-627C00CFA718Q36634134-E2BF26FC-60E9-4B06-95C2-3DE53086074FQ37096570-7DD9DC26-42C7-418E-98E8-217B845D5738Q37609786-9EE57E10-3B08-4CBF-8C82-0C2C068D7508Q37810218-A4C079A5-997B-4EA1-89DE-4604BD08654CQ38094677-03BC1FC7-6981-4431-A456-E6DF8D44BDBEQ38103883-0E54474B-C642-47EA-AB22-D907F2692C93Q38229813-59F85991-980A-4EA4-A727-9B6F83C81C95Q38876360-42D96819-18E6-4EC3-AC5F-F59E7C32D6E2Q38987211-2F37392E-6839-4BA7-BF9A-BCD0ED3C35C1Q39161011-FCEF60EA-ACE7-4A2C-ABE9-AC6862DE6C1BQ39810650-49842110-D925-4D7A-8CF0-7CBF3A1D43C4Q39816043-61330A4D-940A-41C7-82E5-E1A27B5F102AQ40768873-3152C118-D22C-46B2-B96C-38087558B249Q41434430-4DAFA606-F13A-4972-9ABE-1C36FD123F37Q42036323-7F954C93-EA5A-4FC7-BBDD-BD83C2531A82Q44761971-83A09229-BA8E-4A70-A227-8EA86BA677CEQ50898220-D3446501-B412-4F60-9E5E-77958D9059CEQ51289585-875B748C-57B0-43D9-8AFA-4F674C1FEAC0
P2860
An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
An overview of the pharmacokin ...... approved for use in psoriasis.
@ast
An overview of the pharmacokin ...... approved for use in psoriasis.
@en
type
label
An overview of the pharmacokin ...... approved for use in psoriasis.
@ast
An overview of the pharmacokin ...... approved for use in psoriasis.
@en
prefLabel
An overview of the pharmacokin ...... approved for use in psoriasis.
@ast
An overview of the pharmacokin ...... approved for use in psoriasis.
@en
P2093
P2860
P356
P1476
An overview of the pharmacokin ...... approved for use in psoriasis.
@en
P2093
Amita Joshi
Cecelia Leddy
Mark White
Marvin Garovoy
Patricia Walicke
Peter Compton
Peter Kuebler
Robert Bauer
Russell Dedrick
P2860
P356
10.1177/0091270005283282
P577
2006-01-01T00:00:00Z